nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—SLC6A4—chronic obstructive pulmonary disease	0.28	0.565	CbGaD
Atomoxetine—HTR2A—chronic obstructive pulmonary disease	0.215	0.435	CbGaD
Atomoxetine—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0411	0.145	CbGbCtD
Atomoxetine—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0411	0.145	CbGbCtD
Atomoxetine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0313	0.11	CbGbCtD
Atomoxetine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0313	0.11	CbGbCtD
Atomoxetine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0279	0.0985	CbGbCtD
Atomoxetine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0262	0.0927	CbGbCtD
Atomoxetine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0177	0.0626	CbGbCtD
Atomoxetine—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0173	0.061	CbGbCtD
Atomoxetine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0169	0.0597	CbGbCtD
Atomoxetine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0151	0.0532	CbGbCtD
Atomoxetine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00884	0.0312	CbGbCtD
Atomoxetine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00835	0.0295	CbGbCtD
Atomoxetine—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.00625	0.417	CbGeAlD
Atomoxetine—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.00227	0.151	CbGeAlD
Atomoxetine—NPY1R—lung—chronic obstructive pulmonary disease	0.000993	0.0663	CbGeAlD
Atomoxetine—SLC6A3—respiratory system—chronic obstructive pulmonary disease	0.000787	0.0525	CbGeAlD
Atomoxetine—SLC6A4—respiratory system—chronic obstructive pulmonary disease	0.000721	0.0481	CbGeAlD
Atomoxetine—HTR1D—connective tissue—chronic obstructive pulmonary disease	0.000676	0.0451	CbGeAlD
Atomoxetine—SLC6A2—respiratory system—chronic obstructive pulmonary disease	0.000635	0.0424	CbGeAlD
Atomoxetine—SLC6A3—lung—chronic obstructive pulmonary disease	0.000418	0.0279	CbGeAlD
Atomoxetine—SLC6A4—lung—chronic obstructive pulmonary disease	0.000383	0.0256	CbGeAlD
Atomoxetine—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.000382	0.0255	CbGeAlD
Atomoxetine—SLC6A2—lung—chronic obstructive pulmonary disease	0.000337	0.0225	CbGeAlD
Atomoxetine—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.000336	0.0224	CbGeAlD
Atomoxetine—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.000307	0.0205	CbGeAlD
Atomoxetine—Reboxetine—SLC6A4—chronic obstructive pulmonary disease	0.000295	0.0553	CrCbGaD
Atomoxetine—HTR2A—trachea—chronic obstructive pulmonary disease	0.000282	0.0188	CbGeAlD
Atomoxetine—Protriptyline—SLC6A4—chronic obstructive pulmonary disease	0.000271	0.0507	CrCbGaD
Atomoxetine—Ketoprofen—CXCL8—chronic obstructive pulmonary disease	0.000263	0.0493	CrCbGaD
Atomoxetine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000245	0.00163	CcSEcCtD
Atomoxetine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000245	0.00163	CcSEcCtD
Atomoxetine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000245	0.00162	CcSEcCtD
Atomoxetine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000245	0.00162	CcSEcCtD
Atomoxetine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000244	0.00162	CcSEcCtD
Atomoxetine—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000244	0.00162	CcSEcCtD
Atomoxetine—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000243	0.00161	CcSEcCtD
Atomoxetine—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000242	0.00161	CcSEcCtD
Atomoxetine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.00024	0.00159	CcSEcCtD
Atomoxetine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000238	0.00157	CcSEcCtD
Atomoxetine—Affect lability—Prednisolone—chronic obstructive pulmonary disease	0.000236	0.00157	CcSEcCtD
Atomoxetine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00156	CcSEcCtD
Atomoxetine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000236	0.00156	CcSEcCtD
Atomoxetine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000236	0.00156	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000234	0.00155	CcSEcCtD
Atomoxetine—Ephedrine—ADRB2—chronic obstructive pulmonary disease	0.000233	0.0437	CrCbGaD
Atomoxetine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000233	0.00154	CcSEcCtD
Atomoxetine—Cough—Formoterol—chronic obstructive pulmonary disease	0.000233	0.00154	CcSEcCtD
Atomoxetine—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000233	0.00154	CcSEcCtD
Atomoxetine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.00153	CcSEcCtD
Atomoxetine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000231	0.00153	CcSEcCtD
Atomoxetine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000231	0.00153	CcSEcCtD
Atomoxetine—Cough—Montelukast—chronic obstructive pulmonary disease	0.000228	0.00151	CcSEcCtD
Atomoxetine—Mood swings—Prednisolone—chronic obstructive pulmonary disease	0.000228	0.00151	CcSEcCtD
Atomoxetine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000228	0.00151	CcSEcCtD
Atomoxetine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00151	CcSEcCtD
Atomoxetine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00151	CcSEcCtD
Atomoxetine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00151	CcSEcCtD
Atomoxetine—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00151	CcSEcCtD
Atomoxetine—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00151	CcSEcCtD
Atomoxetine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00151	CcSEcCtD
Atomoxetine—Duloxetine—SLC6A4—chronic obstructive pulmonary disease	0.000227	0.0425	CrCbGaD
Atomoxetine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000227	0.0015	CcSEcCtD
Atomoxetine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000227	0.0015	CcSEcCtD
Atomoxetine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.0015	CcSEcCtD
Atomoxetine—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.0015	CcSEcCtD
Atomoxetine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000226	0.0015	CcSEcCtD
Atomoxetine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000226	0.0015	CcSEcCtD
Atomoxetine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000226	0.0015	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000226	0.0015	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000226	0.0015	CcSEcCtD
Atomoxetine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.00148	CcSEcCtD
Atomoxetine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000223	0.00147	CcSEcCtD
Atomoxetine—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000223	0.00147	CcSEcCtD
Atomoxetine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000222	0.00147	CcSEcCtD
Atomoxetine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000222	0.00147	CcSEcCtD
Atomoxetine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000222	0.00147	CcSEcCtD
Atomoxetine—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00147	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000221	0.00146	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000221	0.00146	CcSEcCtD
Atomoxetine—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00146	CcSEcCtD
Atomoxetine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.00143	CcSEcCtD
Atomoxetine—Infection—Formoterol—chronic obstructive pulmonary disease	0.000217	0.00143	CcSEcCtD
Atomoxetine—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00142	CcSEcCtD
Atomoxetine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00142	CcSEcCtD
Atomoxetine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00142	CcSEcCtD
Atomoxetine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000215	0.00142	CcSEcCtD
Atomoxetine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00142	CcSEcCtD
Atomoxetine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000214	0.00142	CcSEcCtD
Atomoxetine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000214	0.00142	CcSEcCtD
Atomoxetine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000214	0.00141	CcSEcCtD
Atomoxetine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000213	0.00141	CcSEcCtD
Atomoxetine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000213	0.00141	CcSEcCtD
Atomoxetine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000212	0.0014	CcSEcCtD
Atomoxetine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000212	0.0014	CcSEcCtD
Atomoxetine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000212	0.0014	CcSEcCtD
Atomoxetine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00021	0.00139	CcSEcCtD
Atomoxetine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000209	0.00139	CcSEcCtD
Atomoxetine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000207	0.00137	CcSEcCtD
Atomoxetine—Duloxetine—CYP1A2—chronic obstructive pulmonary disease	0.000207	0.0387	CrCbGaD
Atomoxetine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00135	CcSEcCtD
Atomoxetine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000203	0.00134	CcSEcCtD
Atomoxetine—HTR2A—lung—chronic obstructive pulmonary disease	0.000203	0.0135	CbGeAlD
Atomoxetine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00134	CcSEcCtD
Atomoxetine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000202	0.00134	CcSEcCtD
Atomoxetine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000202	0.00134	CcSEcCtD
Atomoxetine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.00133	CcSEcCtD
Atomoxetine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.00132	CcSEcCtD
Atomoxetine—Pseudoephedrine—TNF—chronic obstructive pulmonary disease	0.0002	0.0374	CrCbGaD
Atomoxetine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.00132	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000199	0.00132	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000199	0.00132	CcSEcCtD
Atomoxetine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000197	0.00131	CcSEcCtD
Atomoxetine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.00131	CcSEcCtD
Atomoxetine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000196	0.0013	CcSEcCtD
Atomoxetine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000196	0.0013	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000195	0.00129	CcSEcCtD
Atomoxetine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000194	0.00128	CcSEcCtD
Atomoxetine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000194	0.00128	CcSEcCtD
Atomoxetine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00128	CcSEcCtD
Atomoxetine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.00127	CcSEcCtD
Atomoxetine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000192	0.00127	CcSEcCtD
Atomoxetine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000192	0.00127	CcSEcCtD
Atomoxetine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000191	0.00127	CcSEcCtD
Atomoxetine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00019	0.00126	CcSEcCtD
Atomoxetine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000189	0.00125	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000188	0.00125	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000188	0.00125	CcSEcCtD
Atomoxetine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000188	0.00124	CcSEcCtD
Atomoxetine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000188	0.00124	CcSEcCtD
Atomoxetine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000188	0.00124	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.00124	CcSEcCtD
Atomoxetine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00123	CcSEcCtD
Atomoxetine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00123	CcSEcCtD
Atomoxetine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00123	CcSEcCtD
Atomoxetine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00123	CcSEcCtD
Atomoxetine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00123	CcSEcCtD
Atomoxetine—Fluoxetine—SLC6A4—chronic obstructive pulmonary disease	0.000185	0.0346	CrCbGaD
Atomoxetine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.00122	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000184	0.00122	CcSEcCtD
Atomoxetine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000184	0.00122	CcSEcCtD
Atomoxetine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.00121	CcSEcCtD
Atomoxetine—Pain—Montelukast—chronic obstructive pulmonary disease	0.000183	0.00121	CcSEcCtD
Atomoxetine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000182	0.00121	CcSEcCtD
Atomoxetine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.0012	CcSEcCtD
Atomoxetine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000181	0.0012	CcSEcCtD
Atomoxetine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00018	0.00119	CcSEcCtD
Atomoxetine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.00018	0.00119	CcSEcCtD
Atomoxetine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00119	CcSEcCtD
Atomoxetine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00119	CcSEcCtD
Atomoxetine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000179	0.00119	CcSEcCtD
Atomoxetine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.00118	CcSEcCtD
Atomoxetine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000179	0.00118	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000178	0.00118	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000178	0.00118	CcSEcCtD
Atomoxetine—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000178	0.00118	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00118	CcSEcCtD
Atomoxetine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.00118	CcSEcCtD
Atomoxetine—Pseudoephedrine—ADRB2—chronic obstructive pulmonary disease	0.000177	0.0331	CrCbGaD
Atomoxetine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.00117	CcSEcCtD
Atomoxetine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.00117	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000175	0.00116	CcSEcCtD
Atomoxetine—Duloxetine—HTR2A—chronic obstructive pulmonary disease	0.000174	0.0327	CrCbGaD
Atomoxetine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000173	0.00115	CcSEcCtD
Atomoxetine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000173	0.00115	CcSEcCtD
Atomoxetine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000172	0.00114	CcSEcCtD
Atomoxetine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000172	0.00114	CcSEcCtD
Atomoxetine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000172	0.00114	CcSEcCtD
Atomoxetine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000172	0.00114	CcSEcCtD
Atomoxetine—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000172	0.00114	CcSEcCtD
Atomoxetine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000172	0.00114	CcSEcCtD
Atomoxetine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.00017	0.00113	CcSEcCtD
Atomoxetine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00017	0.00113	CcSEcCtD
Atomoxetine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00017	0.00113	CcSEcCtD
Atomoxetine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00017	0.00113	CcSEcCtD
Atomoxetine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00112	CcSEcCtD
Atomoxetine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00112	CcSEcCtD
Atomoxetine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000169	0.00112	CcSEcCtD
Atomoxetine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000169	0.00112	CcSEcCtD
Atomoxetine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000169	0.00112	CcSEcCtD
Atomoxetine—Fluoxetine—CYP1A2—chronic obstructive pulmonary disease	0.000168	0.0315	CrCbGaD
Atomoxetine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00111	CcSEcCtD
Atomoxetine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000167	0.0011	CcSEcCtD
Atomoxetine—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000165	0.00109	CcSEcCtD
Atomoxetine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00108	CcSEcCtD
Atomoxetine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.00108	CcSEcCtD
Atomoxetine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.00108	CcSEcCtD
Atomoxetine—Pseudoephedrine—SLC6A4—chronic obstructive pulmonary disease	0.000161	0.0301	CrCbGaD
Atomoxetine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00016	0.00106	CcSEcCtD
Atomoxetine—Warfarin—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.0298	CrCbGaD
Atomoxetine—Maprotiline—CYP1A2—chronic obstructive pulmonary disease	0.000157	0.0295	CrCbGaD
Atomoxetine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000156	0.00104	CcSEcCtD
Atomoxetine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000156	0.00104	CcSEcCtD
Atomoxetine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000154	0.00102	CcSEcCtD
Atomoxetine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000154	0.00102	CcSEcCtD
Atomoxetine—Warfarin—CYP1A2—chronic obstructive pulmonary disease	0.000154	0.0288	CrCbGaD
Atomoxetine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000153	0.00101	CcSEcCtD
Atomoxetine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000151	0.001	CcSEcCtD
Atomoxetine—Propafenone—CYP1A2—chronic obstructive pulmonary disease	0.00015	0.0281	CrCbGaD
Atomoxetine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000149	0.000988	CcSEcCtD
Atomoxetine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000149	0.000988	CcSEcCtD
Atomoxetine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000148	0.000978	CcSEcCtD
Atomoxetine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000147	0.000973	CcSEcCtD
Atomoxetine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000146	0.000967	CcSEcCtD
Atomoxetine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.000964	CcSEcCtD
Atomoxetine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000144	0.000955	CcSEcCtD
Atomoxetine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000144	0.000955	CcSEcCtD
Atomoxetine—Fluoxetine—HTR2A—chronic obstructive pulmonary disease	0.000142	0.0266	CrCbGaD
Atomoxetine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000141	0.000935	CcSEcCtD
Atomoxetine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.000933	CcSEcCtD
Atomoxetine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000139	0.00092	CcSEcCtD
Atomoxetine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000139	0.000918	CcSEcCtD
Atomoxetine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000139	0.000918	CcSEcCtD
Atomoxetine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000137	0.00091	CcSEcCtD
Atomoxetine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.00091	CcSEcCtD
Atomoxetine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.000909	CcSEcCtD
Atomoxetine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000137	0.000909	CcSEcCtD
Atomoxetine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000137	0.000904	CcSEcCtD
Atomoxetine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.000904	CcSEcCtD
Atomoxetine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000904	CcSEcCtD
Atomoxetine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000903	CcSEcCtD
Atomoxetine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000136	0.000901	CcSEcCtD
Atomoxetine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000136	0.000899	CcSEcCtD
Atomoxetine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000135	0.000891	CcSEcCtD
Atomoxetine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000135	0.000891	CcSEcCtD
Atomoxetine—Depression—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000888	CcSEcCtD
Atomoxetine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000134	0.000886	CcSEcCtD
Atomoxetine—Maprotiline—HTR2A—chronic obstructive pulmonary disease	0.000133	0.0249	CrCbGaD
Atomoxetine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000131	0.000867	CcSEcCtD
Atomoxetine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.000861	CcSEcCtD
Atomoxetine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.000859	CcSEcCtD
Atomoxetine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.000859	CcSEcCtD
Atomoxetine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.000859	CcSEcCtD
Atomoxetine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000129	0.000857	CcSEcCtD
Atomoxetine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000129	0.000857	CcSEcCtD
Atomoxetine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000129	0.000854	CcSEcCtD
Atomoxetine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.000842	CcSEcCtD
Atomoxetine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000127	0.00084	CcSEcCtD
Atomoxetine—Phenoxybenzamine—ADRB2—chronic obstructive pulmonary disease	0.000126	0.0236	CrCbGaD
Atomoxetine—Modafinil—CYP1A2—chronic obstructive pulmonary disease	0.000126	0.0236	CrCbGaD
Atomoxetine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.00083	CcSEcCtD
Atomoxetine—Propranolol—ADRB2—chronic obstructive pulmonary disease	0.000124	0.0233	CrCbGaD
Atomoxetine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000122	0.00081	CcSEcCtD
Atomoxetine—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000796	CcSEcCtD
Atomoxetine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.000769	CcSEcCtD
Atomoxetine—Fenoprofen—ALB—chronic obstructive pulmonary disease	0.000116	0.0217	CrCbGaD
Atomoxetine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000115	0.000763	CcSEcCtD
Atomoxetine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.000756	CcSEcCtD
Atomoxetine—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000742	CcSEcCtD
Atomoxetine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000725	CcSEcCtD
Atomoxetine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.000707	CcSEcCtD
Atomoxetine—Propranolol—CYP1A1—chronic obstructive pulmonary disease	0.000107	0.02	CrCbGaD
Atomoxetine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000702	CcSEcCtD
Atomoxetine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000106	0.0007	CcSEcCtD
Atomoxetine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000696	CcSEcCtD
Atomoxetine—Nortriptyline—SLC6A4—chronic obstructive pulmonary disease	0.000104	0.0194	CrCbGaD
Atomoxetine—Propranolol—CYP1A2—chronic obstructive pulmonary disease	0.000103	0.0193	CrCbGaD
Atomoxetine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000668	CcSEcCtD
Atomoxetine—Phenprocoumon—ALB—chronic obstructive pulmonary disease	0.0001	0.0187	CrCbGaD
Atomoxetine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	9.91e-05	0.000656	CcSEcCtD
Atomoxetine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	9.73e-05	0.000644	CcSEcCtD
Atomoxetine—Fluoxetine—ALB—chronic obstructive pulmonary disease	9.73e-05	0.0182	CrCbGaD
Atomoxetine—Agitation—Prednisone—chronic obstructive pulmonary disease	9.66e-05	0.00064	CcSEcCtD
Atomoxetine—Nortriptyline—CYP1A2—chronic obstructive pulmonary disease	9.45e-05	0.0177	CrCbGaD
Atomoxetine—Vertigo—Prednisone—chronic obstructive pulmonary disease	9.44e-05	0.000625	CcSEcCtD
Atomoxetine—Syncope—Prednisone—chronic obstructive pulmonary disease	9.43e-05	0.000624	CcSEcCtD
Atomoxetine—Desipramine—ADRB2—chronic obstructive pulmonary disease	9.41e-05	0.0176	CrCbGaD
Atomoxetine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	9.38e-05	0.000621	CcSEcCtD
Atomoxetine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	9.24e-05	0.000612	CcSEcCtD
Atomoxetine—Convulsion—Prednisone—chronic obstructive pulmonary disease	9.11e-05	0.000603	CcSEcCtD
Atomoxetine—Myalgia—Prednisone—chronic obstructive pulmonary disease	8.95e-05	0.000593	CcSEcCtD
Atomoxetine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	8.95e-05	0.000593	CcSEcCtD
Atomoxetine—Anxiety—Prednisone—chronic obstructive pulmonary disease	8.92e-05	0.000591	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.89e-05	0.000588	CcSEcCtD
Atomoxetine—Warfarin—ALB—chronic obstructive pulmonary disease	8.87e-05	0.0166	CrCbGaD
Atomoxetine—Diphenhydramine—CYP1A2—chronic obstructive pulmonary disease	8.74e-05	0.0164	CrCbGaD
Atomoxetine—Desipramine—SLC6A4—chronic obstructive pulmonary disease	8.55e-05	0.016	CrCbGaD
Atomoxetine—Infection—Prednisone—chronic obstructive pulmonary disease	8.52e-05	0.000564	CcSEcCtD
Atomoxetine—Shock—Prednisone—chronic obstructive pulmonary disease	8.44e-05	0.000559	CcSEcCtD
Atomoxetine—Methadone—CYP1A2—chronic obstructive pulmonary disease	8.44e-05	0.0158	CrCbGaD
Atomoxetine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	8.41e-05	0.000557	CcSEcCtD
Atomoxetine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	8.37e-05	0.000554	CcSEcCtD
Atomoxetine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	8.33e-05	0.000552	CcSEcCtD
Atomoxetine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	8.29e-05	0.000549	CcSEcCtD
Atomoxetine—Anorexia—Prednisone—chronic obstructive pulmonary disease	8.18e-05	0.000541	CcSEcCtD
Atomoxetine—Nortriptyline—HTR2A—chronic obstructive pulmonary disease	7.98e-05	0.0149	CrCbGaD
Atomoxetine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.82e-05	0.000518	CcSEcCtD
Atomoxetine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.81e-05	0.000517	CcSEcCtD
Atomoxetine—Desipramine—CYP1A2—chronic obstructive pulmonary disease	7.78e-05	0.0146	CrCbGaD
Atomoxetine—Insomnia—Prednisone—chronic obstructive pulmonary disease	7.76e-05	0.000514	CcSEcCtD
Atomoxetine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	7.7e-05	0.00051	CcSEcCtD
Atomoxetine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	7.55e-05	0.0005	CcSEcCtD
Atomoxetine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	7.46e-05	0.000494	CcSEcCtD
Atomoxetine—Rash—Prednisolone—chronic obstructive pulmonary disease	7.44e-05	0.000493	CcSEcCtD
Atomoxetine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	7.44e-05	0.000492	CcSEcCtD
Atomoxetine—Fatigue—Prednisone—chronic obstructive pulmonary disease	7.4e-05	0.00049	CcSEcCtD
Atomoxetine—Headache—Prednisolone—chronic obstructive pulmonary disease	7.4e-05	0.00049	CcSEcCtD
Atomoxetine—Constipation—Prednisone—chronic obstructive pulmonary disease	7.34e-05	0.000486	CcSEcCtD
Atomoxetine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	7.07e-05	0.000468	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	7.02e-05	0.000465	CcSEcCtD
Atomoxetine—Nausea—Prednisolone—chronic obstructive pulmonary disease	7.01e-05	0.000464	CcSEcCtD
Atomoxetine—Ketoprofen—ALB—chronic obstructive pulmonary disease	6.84e-05	0.0128	CrCbGaD
Atomoxetine—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.82e-05	0.000451	CcSEcCtD
Atomoxetine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.78e-05	0.000449	CcSEcCtD
Atomoxetine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.78e-05	0.000449	CcSEcCtD
Atomoxetine—Desipramine—HTR2A—chronic obstructive pulmonary disease	6.57e-05	0.0123	CrCbGaD
Atomoxetine—Asthenia—Prednisone—chronic obstructive pulmonary disease	6.16e-05	0.000408	CcSEcCtD
Atomoxetine—Pruritus—Prednisone—chronic obstructive pulmonary disease	6.07e-05	0.000402	CcSEcCtD
Atomoxetine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.87e-05	0.000389	CcSEcCtD
Atomoxetine—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.67e-05	0.000376	CcSEcCtD
Atomoxetine—Nortriptyline—ALB—chronic obstructive pulmonary disease	5.46e-05	0.0102	CrCbGaD
Atomoxetine—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.45e-05	0.000361	CcSEcCtD
Atomoxetine—Rash—Prednisone—chronic obstructive pulmonary disease	5.41e-05	0.000358	CcSEcCtD
Atomoxetine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.4e-05	0.000358	CcSEcCtD
Atomoxetine—Headache—Prednisone—chronic obstructive pulmonary disease	5.37e-05	0.000356	CcSEcCtD
Atomoxetine—Nausea—Prednisone—chronic obstructive pulmonary disease	5.1e-05	0.000337	CcSEcCtD
Atomoxetine—HTR2A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	3.9e-05	0.000762	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.87e-05	0.000757	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	3.86e-05	0.000755	CbGpPWpGaD
Atomoxetine—SLC6A3—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.84e-05	0.000751	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	3.83e-05	0.000748	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.82e-05	0.000747	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	3.7e-05	0.000724	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.67e-05	0.000718	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.66e-05	0.000716	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.66e-05	0.000715	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.64e-05	0.000712	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.62e-05	0.000708	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.62e-05	0.000707	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	3.6e-05	0.000705	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.59e-05	0.000702	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	3.54e-05	0.000692	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.5e-05	0.000685	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	3.49e-05	0.000682	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.46e-05	0.000676	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.43e-05	0.000671	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.36e-05	0.000657	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.3e-05	0.000646	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.29e-05	0.000642	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.27e-05	0.000639	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.26e-05	0.000637	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.26e-05	0.000637	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.24e-05	0.000634	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.24e-05	0.000633	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	3.21e-05	0.000628	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	3.21e-05	0.000628	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.18e-05	0.000621	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.18e-05	0.000621	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.14e-05	0.000614	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.14e-05	0.000614	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	3.14e-05	0.000613	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.12e-05	0.000609	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.08e-05	0.000603	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.06e-05	0.000598	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3e-05	0.000586	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.95e-05	0.000577	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.94e-05	0.000575	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.85e-05	0.000558	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.8e-05	0.000547	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.78e-05	0.000543	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.76e-05	0.000539	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.75e-05	0.000539	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.75e-05	0.000539	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.73e-05	0.000534	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.72e-05	0.000532	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.72e-05	0.000531	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	2.69e-05	0.000526	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.68e-05	0.000524	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.68e-05	0.000523	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.64e-05	0.000515	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.63e-05	0.000515	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.62e-05	0.000511	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.61e-05	0.000511	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.56e-05	0.000501	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.56e-05	0.0005	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.56e-05	0.0005	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.55e-05	0.000498	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.53e-05	0.000495	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.51e-05	0.000492	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.5e-05	0.000489	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.5e-05	0.000488	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.48e-05	0.000485	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.44e-05	0.000477	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.43e-05	0.000475	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.41e-05	0.000471	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.41e-05	0.000471	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.4e-05	0.000469	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.39e-05	0.000468	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.37e-05	0.000463	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.34e-05	0.000458	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.29e-05	0.000448	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.27e-05	0.000444	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.21e-05	0.000432	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.2e-05	0.000429	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.19e-05	0.000428	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.18e-05	0.000427	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.17e-05	0.000425	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.17e-05	0.000424	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.16e-05	0.000423	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.13e-05	0.000416	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.13e-05	0.000416	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.11e-05	0.000412	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.09e-05	0.000409	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	2.07e-05	0.000405	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.06e-05	0.000403	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.06e-05	0.000402	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.03e-05	0.000397	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.97e-05	0.000385	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.96e-05	0.000383	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.96e-05	0.000382	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.94e-05	0.00038	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.94e-05	0.000379	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.94e-05	0.000379	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.93e-05	0.000378	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.93e-05	0.000377	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.93e-05	0.000377	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.92e-05	0.000376	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.91e-05	0.000374	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.9e-05	0.000372	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.87e-05	0.000366	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.84e-05	0.00036	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.79e-05	0.00035	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.79e-05	0.00035	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.78e-05	0.000348	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.77e-05	0.000347	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.77e-05	0.000346	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.76e-05	0.000344	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.76e-05	0.000344	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.74e-05	0.00034	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.69e-05	0.00033	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.68e-05	0.000329	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.68e-05	0.000328	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.65e-05	0.000323	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.64e-05	0.000321	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.61e-05	0.000316	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.61e-05	0.000315	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.61e-05	0.000314	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.6e-05	0.000313	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.58e-05	0.000309	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.53e-05	0.0003	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.49e-05	0.000291	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.48e-05	0.000289	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.48e-05	0.000289	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.47e-05	0.000287	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.45e-05	0.000283	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.44e-05	0.000281	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.42e-05	0.000277	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.35e-05	0.000264	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.34e-05	0.000263	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.34e-05	0.000262	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.33e-05	0.000261	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.33e-05	0.00026	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.32e-05	0.000258	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.31e-05	0.000257	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.31e-05	0.000255	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.29e-05	0.000253	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.28e-05	0.000251	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.28e-05	0.00025	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.26e-05	0.000246	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.24e-05	0.000243	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.23e-05	0.000241	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.22e-05	0.000238	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.22e-05	0.000238	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.2e-05	0.000235	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.19e-05	0.000233	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.17e-05	0.000228	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.16e-05	0.000226	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.15e-05	0.000224	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.13e-05	0.000221	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	1.12e-05	0.000218	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.1e-05	0.000214	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.09e-05	0.000213	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.06e-05	0.000207	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.04e-05	0.000204	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.04e-05	0.000203	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.03e-05	0.000201	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	1.02e-05	0.000199	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.95e-06	0.000195	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.89e-06	0.000193	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.88e-06	0.000193	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.81e-06	0.000192	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.6e-06	0.000188	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.52e-06	0.000186	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.52e-06	0.000186	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.45e-06	0.000185	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.43e-06	0.000184	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.39e-06	0.000184	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	9.38e-06	0.000183	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.36e-06	0.000183	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.16e-06	0.000179	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9e-06	0.000176	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.93e-06	0.000175	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.85e-06	0.000173	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.75e-06	0.000171	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.64e-06	0.000169	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.64e-06	0.000169	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.59e-06	0.000168	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.99e-06	0.000156	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.92e-06	0.000155	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.83e-06	0.000153	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.76e-06	0.000152	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.73e-06	0.000151	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.68e-06	0.00015	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.59e-06	0.000148	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.54e-06	0.000147	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.38e-06	0.000144	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.28e-06	0.000142	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.22e-06	0.000141	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.21e-06	0.000141	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.2e-06	0.000141	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.17e-06	0.00014	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.11e-06	0.000139	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.02e-06	0.000137	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.94e-06	0.000136	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.83e-06	0.000133	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.8e-06	0.000133	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	6.72e-06	0.000131	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.63e-06	0.00013	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.62e-06	0.000129	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.49e-06	0.000127	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.44e-06	0.000126	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.32e-06	0.000124	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.3e-06	0.000123	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.28e-06	0.000123	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	6.13e-06	0.00012	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.03e-06	0.000118	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.95e-06	0.000116	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.91e-06	0.000116	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.88e-06	0.000115	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.84e-06	0.000114	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.79e-06	0.000113	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.78e-06	0.000113	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.76e-06	0.000113	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.67e-06	0.000111	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.65e-06	0.00011	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.59e-06	0.000109	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.32e-06	0.000104	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.11e-06	9.98e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.9e-06	9.58e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.86e-06	9.51e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.86e-06	9.49e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.78e-06	9.34e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.76e-06	9.31e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.71e-06	9.21e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.65e-06	9.08e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	4.64e-06	9.07e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.62e-06	9.03e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.49e-06	8.77e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.45e-06	8.7e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	4.44e-06	8.68e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.38e-06	8.57e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.36e-06	8.52e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.33e-06	8.46e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.3e-06	8.4e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.27e-06	8.34e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.15e-06	8.11e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.1e-06	8.02e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.08e-06	7.98e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.81e-06	7.44e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.73e-06	7.3e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.61e-06	7.06e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.3e-06	6.46e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.13e-06	6.13e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.87e-06	5.61e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.79e-06	5.45e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.67e-06	5.22e-05	CbGpPWpGaD
